Incidence of mortality and viral load suppression by clinical characteristics among participants in HIV care facilities in Bauchi State, 2020-2022. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Cumulative treatment outcomes prevalence rates for patients in ART treatment from year 2020 to 2022 for study participant in Bauchi State. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Survival function analysis for LTFU according to Viral Load status and BMI status. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Demographic characteristics of study participants from two ART facilities in Bauchi state, based on data retrieved covering a three-year period from 2020 to 2022. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Annual incidence rate per 100 person-years trend for ART treatment outcomes. by Ekerette Emmanuel Udoh (7326194)

Subjects:

Example of coloration measurement taken in ImageJ for <i>M</i>. <i>mercenaria</i> specimen w48 at the conclusion of the 20.5-week experiment. by Teagan McMahon (20108036)

Subjects:

Subset of juvenile <i>M</i>. <i>arenaria</i> specimens at the end of the experiment. by Teagan McMahon (20108036)

Subjects:

Comparison of study groups based on patients’ variables before and after administration of study drugs. by Nadia Gul (249538)

Subjects:

Growth and color data for all specimens and tank temperature and pH conditions. by Teagan McMahon (20108036)

Subjects:

Schematic of the experimental design of the pH and temperature-controlled culture experiment in Schiller Coastal Studies Center (SCSC; Bowdoin College, Orr’s Island, ME). by Teagan McMahon (20108036)

Subjects:

Flow chart of patient’s recruitment and participation. by Nadia Gul (249538)

Subjects:

Comparative analyses of group 1 vs group 2 based on various patient characteristics. by Nadia Gul (249538)

Subjects:

Average experimental conditions (± standard deviation) for each tank. by Teagan McMahon (20108036)

Subjects:

Visual examples of the change in maximum height measure. by Teagan McMahon (20108036)

Subjects:

Frequency of hypoglycemic episodes in group 1 vs group 2. by Nadia Gul (249538)

Subjects:

Demographics and baseline characteristics of patients. by Nadia Gul (249538)

Subjects:

Parameter estimates from the final models for <i>M</i>. <i>mercenaria</i> & <i>M</i>. <i>arenaria</i> mortality. by Teagan McMahon (20108036)

Subjects:

Impact of group 1 and group 2 drugs on hyperglycemia based on HbA1c levels before and after 3 months of administration. by Nadia Gul (249538)

Subjects:

Additional questions on vaccination. by Sara Saleh (6733619)

Subjects:

Socio-demographic characteristics of the population. by Sara Saleh (6733619)

Subjects: